Inflammatory cell recruitment in cardiovascular disease: murine models and potential clinical applications

2010 ◽  
Vol 118 (11) ◽  
pp. 641-655 ◽  
Author(s):  
Eileen McNeill ◽  
Keith M. Channon ◽  
David R. Greaves

Atherosclerosis is the pathological process that underlies the development of cardiovascular disease, a leading cause of mortality. Atherosclerotic plaque formation is driven by the recruitment of inflammatory monocytes into the artery wall, their differentiation into macrophages and the subsequent transformation of macrophages into cholesterol-laden foam cells. Models of hypercholesterolaemia such as the ApoE (apolipoprotein E)−/− mouse and the application of transgenic technologies have allowed us to undertake a thorough dissection of the cellular and molecular biology of the atherosclerotic disease process. Murine models have emphasized the central role of inflammation in atherogenesis and have been instrumental in the identification of adhesion molecules that support monocyte recruitment, scavenger receptors that facilitate cholesterol uptake by macrophages and other macrophage activation receptors. The study of mice deficient in multiple members of the chemokine family, and their receptors, has shown that chemokines play a critical role in promoting atherosclerotic plaque formation. In the present review, we will discuss novel therapeutic avenues for the treatment of cardiovascular disease that derive directly from our current understanding of atherogenesis gained in experimental animal models.

2018 ◽  
Vol 38 (11) ◽  
pp. 2562-2575 ◽  
Author(s):  
Petteri Rinne ◽  
Raquel Guillamat-Prats ◽  
Martina Rami ◽  
Laura Bindila ◽  
Larisa Ring ◽  
...  

2016 ◽  
Vol 473 (10) ◽  
pp. 1281-1295 ◽  
Author(s):  
Arif Yurdagul ◽  
Alexandra C. Finney ◽  
Matthew D. Woolard ◽  
A. Wayne Orr

Changes in the local microenvironment regulate multiple aspects of vascular and inflammatory cell phenotype, determining the location, composition and clinical consequences of atherosclerotic plaque formation.


2017 ◽  
Vol 131 (20) ◽  
pp. 2489-2501 ◽  
Author(s):  
Dawn Thompson ◽  
Nicola Morrice ◽  
Louise Grant ◽  
 Samantha Le Sommer ◽  
Emma K. Lees ◽  
...  

Cardiovascular disease (CVD) is the most prevalent cause of mortality among patients with type 1 or type 2 diabetes, due to accelerated atherosclerosis. Recent evidence suggests a strong link between atherosclerosis and insulin resistance, due to impaired insulin receptor (IR) signalling. Here, we demonstrate that inhibiting the activity of protein tyrosine phosphatase 1B (PTP1B), the major negative regulator of the IR prevents and reverses atherosclerotic plaque formation in an LDLR−/− mouse model of atherosclerosis. Acute (single dose) or chronic PTP1B inhibitor (trodusquemine) treatment of LDLR−/− mice decreased weight gain and adiposity, improved glucose homeostasis and attenuated atherosclerotic plaque formation. This was accompanied by a reduction in both, circulating total cholesterol and triglycerides, a decrease in aortic monocyte chemoattractant protein-1 (MCP-1) expression levels and hyperphosphorylation of aortic Akt/PKB and AMPKα. Our findings are the first to demonstrate that PTP1B inhibitors could be used in prevention and reversal of atherosclerosis development and reduction in CVD risk.


Sign in / Sign up

Export Citation Format

Share Document